Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 402

Showing 1-25 of 402 citing articles:

The IUPHAR/BPS Guide to PHARMACOLOGY in 2024
Simon D Harding, Jane F Armstrong, Elena Faccenda, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D1438-D1449
Open Access | Times Cited: 113
Long COVID: a clinical update
Trisha Greenhalgh, Manoj Sivan, Alice Perlowski, et al.
The Lancet (2024) Vol. 404, Iss. 10453, pp. 707-724
Closed Access | Times Cited: 74
Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19
Amy L. Lightner, Vikram Sengupta, Sascha Qian, et al.
CHEST Journal (2023) Vol. 164, Iss. 6, pp. 1444-1453
Open Access | Times Cited: 53
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li, Yongcheng Song
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115772-115772
Open Access | Times Cited: 52
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 48
Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
Bin Tan, Xiaoming Zhang, Ahmadullah Ansari, et al.
Science (2024) Vol. 383, Iss. 6690, pp. 1434-1440
Open Access | Times Cited: 45
Molecular architecture of coronavirus double-membrane vesicle pore complex
Yixin Huang, Tong-Yun Wang, Lijie Zhong, et al.
Nature (2024) Vol. 633, Iss. 8028, pp. 224-231
Open Access | Times Cited: 16
Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review
Maria Marinescu
Antibiotics (2023) Vol. 12, Iss. 7, pp. 1220-1220
Open Access | Times Cited: 33
Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period
Danyi Ao, Xuemei He, Jian Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 28
Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature
Davide Marangoni, Roberta Maria Antonello, Marco Coppi, et al.
International Journal of Infectious Diseases (2023) Vol. 133, pp. 53-56
Open Access | Times Cited: 27
Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1
Xiong Xie, Qiaoshuai Lan, Jinyi Zhao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 12
SARS-CoV-2 aberrantly elevates mitochondrial bioenergetics to induce robust virus propagation
Hye Jin Shin, Wooseong Lee, Keun Bon Ku, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 12
Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity
Jenny Desantis, Alessandro Bazzacco, Michela Eleuteri, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116202-116202
Open Access | Times Cited: 10
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies
Y.-C. Chung, Ching-Yin Lam, Pak-Hei Tan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8155-8155
Open Access | Times Cited: 10
Conjugated Linolenic Acid (CLnA) vs Conjugated Linoleic Acid (CLA): A Comprehensive Review of Potential Advantages in Molecular Characteristics, Health Benefits, and Production Techniques
Meijun Du, Mengyue Gong, Gangcheng Wu, et al.
Journal of Agricultural and Food Chemistry (2024) Vol. 72, Iss. 11, pp. 5503-5525
Closed Access | Times Cited: 9
Cyclic β2,3-amino acids improve the serum stability of macrocyclic peptide inhibitors targeting the SARS-CoV-2 main protease
Takashi Miura, Tika R. Malla, Lennart Brewitz, et al.
Bulletin of the Chemical Society of Japan (2024) Vol. 97, Iss. 5
Open Access | Times Cited: 8
A generalized framework to identify SARS-CoV-2 broadly neutralizing antibodies
Fanchong Jian, Anna Z. Wec, Leilei Feng, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 8
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 8
Novel treatment strategy targeting interleukin-6 induced by cancer associated fibroblasts for peritoneal metastasis of gastric cancer
Ema Mitsui, Satoru Kikuchi, Tomohiro Okura, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
The Effect of HBV Therapy on Glycemic Control in HBV‐Infected Patients With Diabetes: A 90‐day Multicenter Study
Qi Liu, Jie Huang, Jingyi Hu, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 2
Closed Access | Times Cited: 1
In vivo production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection
Yuta Suzuki, Takayuki Miyazaki, Yoko Ida, et al.
Molecular Therapy — Nucleic Acids (2025) Vol. 36, Iss. 1, pp. 102467-102467
Open Access | Times Cited: 1
Systematic Reevaluation of Repurposed Drugs Against the Main Protease of SARS‐CoV‐2 via Combined Experiments
Jialu Ye, Rui Zhang, Jiahao Zhou, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 2
Closed Access | Times Cited: 1
Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates
Prakash D. Jadhav, Xueying Liang, Ahmadullah Ansari, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
A coronavirus assembly inhibitor that targets the viral membrane protein
Manon Laporte, Dirk Jochmans, Dorothée Bardiot, et al.
Nature (2025)
Open Access | Times Cited: 1
A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein
Ellen Van Damme, Pravien Abeywickrema, Yanting Yin, et al.
Nature (2025)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top